US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
PT1516628E
(pt)
*
|
1995-07-27 |
2013-09-24 |
Genentech Inc |
Formulação de proteína liofilizada isotónica estável
|
GB9610992D0
(en)
*
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
EP0852951A1
(de)
*
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
ES2190087T3
(es)
*
|
1997-06-13 |
2003-07-16 |
Genentech Inc |
Formulacion estabilizada de un anticuerpo.
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
SK285284B6
(sk)
*
|
1998-03-26 |
2006-10-05 |
Schering Corporation |
Vodný prostriedok umožňujúci stabilizáciu PEG-interferón alfa konjugátov, spôsob výroby lyofilizovaného prášku a výrobok s jeho obsahom
|
EP2311436A1
(en)
|
1998-04-27 |
2011-04-20 |
Altus Pharmaceuticals Inc. |
Stabilized protein crystals, formulations containing them and methods of making them
|
ES2261589T3
(es)
*
|
1998-05-06 |
2006-11-16 |
Genentech, Inc. |
Composicion de anticuerpos anti-her2.
|
US20030166525A1
(en)
|
1998-07-23 |
2003-09-04 |
Hoffmann James Arthur |
FSH Formulation
|
CN1053590C
(zh)
*
|
1998-10-19 |
2000-06-21 |
卫生部长春生物制品研究所 |
冻干甲型肝炎减毒活疫苗及其保护剂
|
PT1124961E
(pt)
|
1998-10-23 |
2007-02-28 |
Amgen Inc |
Compostos trombopoiéticos
|
ATE296839T1
(de)
|
1999-03-01 |
2005-06-15 |
Genentech Inc |
Antikörper zur krebsbehandlung und -diagnose
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
JP4557098B2
(ja)
*
|
1999-03-31 |
2010-10-06 |
味の素株式会社 |
安定な6−アミジノ−2−ナフチル4−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
|
CA2370466C
(en)
|
1999-06-25 |
2011-02-08 |
Sharon Erickson |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
WO2000072873A1
(en)
*
|
1999-05-31 |
2000-12-07 |
Mitsubishi Chemical Corporation |
Freeze dried hgf preparations
|
ATE247981T1
(de)
*
|
1999-06-12 |
2003-09-15 |
Bitop Ag |
Proteinenthaltende pharmazeutische zubereitung
|
GEP20104998B
(en)
|
1999-06-25 |
2010-06-10 |
Genentech Inc |
Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
|
EP1064934A1
(en)
*
|
1999-06-30 |
2001-01-03 |
Applied Research Systems ARS Holding N.V. |
GRF-containing lyophilized pharmaceutical composition
|
US6627196B1
(en)
|
1999-08-27 |
2003-09-30 |
Genentech, Inc. |
Dosages for treatment with anti-ErbB2 antibodies
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
CA2386228A1
(en)
*
|
1999-10-04 |
2001-04-12 |
Chiron Corporation |
Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
|
JP4948731B2
(ja)
*
|
1999-12-02 |
2012-06-06 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
凍結乾燥の際に生物学的分子を安定化するための組成物および方法
|
CN1286969C
(zh)
|
1999-12-14 |
2006-11-29 |
热生物之星公司 |
多肽和抗原的稳定稀释剂
|
GB9930882D0
(en)
*
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
KR20130056201A
(ko)
|
2000-05-19 |
2013-05-29 |
제넨테크, 인크. |
ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
|
CA2411102A1
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
DK1314437T3
(da)
*
|
2000-08-11 |
2014-07-14 |
Chugai Pharmaceutical Co Ltd |
Stabiliserede antistofindeholdende præparater
|
CA2422076A1
(en)
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceutical Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
IL155002A0
(en)
†
|
2000-10-12 |
2003-10-31 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
US7439359B2
(en)
|
2000-11-02 |
2008-10-21 |
Sloan-Kettering Institute For Cancer Research |
Small molecule compositions for binding to hsp90
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
WO2002060485A2
(en)
|
2001-01-31 |
2002-08-08 |
Idec Pharmaceuticals Corporation |
Use of immunoregulatory antibodies in the treatment of neoplastic disorders
|
EP1370292A1
(en)
|
2001-01-31 |
2003-12-17 |
Idec Pharmaceuticals Corporation |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
US7825094B2
(en)
|
2001-05-23 |
2010-11-02 |
Sloan-Kettering Institute For Cancer Research |
Method of treatment for cancers associated with elevated HER 2 levels
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
DE10133394A1
(de)
*
|
2001-07-13 |
2003-01-30 |
Merck Patent Gmbh |
Flüssige Formulierung enthaltend Cetuximab
|
US20030113316A1
(en)
*
|
2001-07-25 |
2003-06-19 |
Kaisheva Elizabet A. |
Stable lyophilized pharmaceutical formulation of IgG antibodies
|
CN1292655C
(zh)
|
2001-11-08 |
2007-01-03 |
蛋白质设计实验室股份有限公司 |
IgG抗体稳定的液态药物制剂
|
CN100415769C
(zh)
*
|
2002-02-07 |
2008-09-03 |
中国科学院过程工程研究所 |
寡聚或多聚亚基蛋白质分离纯化的方法
|
KR20110091822A
(ko)
|
2002-02-14 |
2011-08-12 |
추가이 세이야쿠 가부시키가이샤 |
항체함유 용액제제
|
DE10211227A1
(de)
*
|
2002-03-13 |
2003-10-02 |
Aventis Behring Gmbh |
Verfahren zur Rekonstitution von Iyophilisierten Proteinen
|
DK1501856T3
(da)
|
2002-04-10 |
2013-03-25 |
Genentech Inc |
Anti-HER2 antistofvarianter
|
NZ537610A
(en)
*
|
2002-07-02 |
2006-07-28 |
Smithkline Beecham Corp |
Stable formulations of the C242 antibody
|
CN102295703A
(zh)
|
2002-07-15 |
2011-12-28 |
健泰科生物技术公司 |
鉴定对用抗ErbB2抗体处理响应的肿瘤的方法
|
US20040033228A1
(en)
*
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
ES2629602T5
(es)
|
2002-09-11 |
2021-06-08 |
Genentech Inc |
Purificación de proteínas
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
EP1592440A4
(en)
|
2003-02-10 |
2007-07-11 |
Elan Pharm Inc |
IMMUNOGLOBULIN PREPARATION AND METHOD OF PRODUCING THE SAME
|
US20050142139A1
(en)
*
|
2003-03-21 |
2005-06-30 |
Norbert Schulke |
CD4-IgG2 formulations
|
PL1610822T5
(pl)
|
2003-04-02 |
2019-05-31 |
Ares Trading Sa |
Płynne formulacje farmaceutyczne FSH i LH z niejonowym surfaktantem
|
AU2012200957B2
(en)
*
|
2003-04-04 |
2014-10-23 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
SI2335725T1
(sl)
|
2003-04-04 |
2017-01-31 |
Genentech, Inc. |
Visokokoncentrirane formulacije protiteles in proteinov
|
ZA200507805B
(en)
|
2003-04-09 |
2006-12-27 |
Genentech Inc |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
|
FR2853551B1
(fr)
*
|
2003-04-09 |
2006-08-04 |
Lab Francais Du Fractionnement |
Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
CA2930485C
(en)
|
2003-05-14 |
2018-04-10 |
Immunogen, Inc. |
Maytansinoid-antibody conjugate compositions
|
RS20050885A
(sr)
|
2003-05-30 |
2008-04-04 |
Genentech |
Lečenje sa anti-vegf antitelima
|
JP2007526220A
(ja)
|
2003-06-05 |
2007-09-13 |
ジェネンテック・インコーポレーテッド |
B細胞疾患の併用療法
|
SI1638595T1
(sl)
|
2003-06-20 |
2013-04-30 |
Ares Trading S.A. |
Liofilizirane formulacije fsh/lh
|
PL2107069T3
(pl)
|
2003-08-05 |
2013-06-28 |
Novo Nordisk As |
Nowe pochodne insuliny
|
EP1664398A4
(en)
|
2003-09-03 |
2009-08-26 |
Shmuel Bukshpan |
METHODS AND DEVICES FOR REALIZING RAPID CRYSTALLIZATION OF BIOLOGICAL MOLECULES
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
EA025962B1
(ru)
|
2003-11-05 |
2017-02-28 |
Роше Гликарт Аг |
АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
|
DE10355251A1
(de)
*
|
2003-11-26 |
2005-06-23 |
Merck Patent Gmbh |
Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
WO2005089503A2
(en)
*
|
2004-03-19 |
2005-09-29 |
Progenics Pharmaceuticals, Inc. |
Cd4-igg2 formulations
|
US7319032B2
(en)
|
2004-04-22 |
2008-01-15 |
Medtox |
Non-sugar sweeteners for use in test devices
|
DE102004022927A1
(de)
*
|
2004-05-10 |
2005-12-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
|
US7723306B2
(en)
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
US7611709B2
(en)
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
US7727962B2
(en)
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
JP5234734B2
(ja)
|
2004-06-01 |
2013-07-10 |
ジェネンテック, インコーポレイテッド |
抗体−薬物結合体および方法
|
WO2006014965A2
(en)
*
|
2004-07-27 |
2006-02-09 |
Human Genome Sciences, Inc. |
Pharmaceutical formulation and process
|
US20060051347A1
(en)
*
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
ES2669510T3
(es)
|
2004-09-23 |
2018-05-28 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006060533A2
(en)
|
2004-12-01 |
2006-06-08 |
Genentech, Inc. |
Conjugates of 1, 8-bis-naphthalimides with an antibody
|
EP1827483B1
(en)
|
2004-12-15 |
2014-07-02 |
Swedish Orphan Biovitrum AB (publ) |
Therapeutic formulations of keratinocyte growth factor
|
AU2005325200A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of HER antibodies
|
CN1313161C
(zh)
*
|
2005-01-27 |
2007-05-02 |
北京大学临床肿瘤学院 |
结直肠癌放射免疫导向手术药物及其制备方法
|
US9403828B2
(en)
|
2005-02-01 |
2016-08-02 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule Hsp90 inhibitors
|
WO2006084030A2
(en)
|
2005-02-01 |
2006-08-10 |
Sloan-Kettering Institute For Cancer Research |
Small-molecule hsp90 inhibitors
|
CN103981190A
(zh)
|
2005-02-07 |
2014-08-13 |
罗氏格黎卡特股份公司 |
结合egfr的抗原结合分子,编码它的载体,及其应用
|
JP2008531576A
(ja)
|
2005-02-23 |
2008-08-14 |
ジェネンテック・インコーポレーテッド |
Her二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長
|
ES2633574T3
(es)
*
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
AU2006278573A1
(en)
*
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
AR055137A1
(es)
|
2005-08-26 |
2007-08-08 |
Glycart Biotechnology Ag |
Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
|
JP2009516692A
(ja)
*
|
2005-11-22 |
2009-04-23 |
ワイス |
免疫グロブリン融合タンパク質製剤
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
SI1969007T1
(sl)
|
2005-12-20 |
2014-03-31 |
Bristol-Myers Squibb Company |
Sestavki in postopki za izdelavo sestavka
|
PL1962886T6
(pl)
|
2005-12-20 |
2023-03-13 |
Bristol-Myers Squibb Company |
Stabilne formulacje białkowe
|
AR058568A1
(es)
|
2005-12-20 |
2008-02-13 |
Bristol Myers Squibb Co |
Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
|
CN101389650B
(zh)
|
2005-12-28 |
2012-10-10 |
诺沃-诺迪斯克有限公司 |
包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
|
US7833766B2
(en)
*
|
2006-02-07 |
2010-11-16 |
Shire Human Genetic Therapies, Inc. |
Stabilized compositions of proteins having a free thiol moiety
|
HUE025989T2
(hu)
|
2006-03-21 |
2016-05-30 |
Genentech Inc |
Alfa5béta1-antagonistákat magában foglaló kombinációs terápia
|
EP2004221A2
(en)
|
2006-03-23 |
2008-12-24 |
Novartis Pharma AG |
Anti-tumor cell antigen antibody therapeutics
|
EP2738179A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
EP2010214A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
JO3324B1
(ar)
*
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
AU2011265555B2
(en)
*
|
2006-04-21 |
2016-03-10 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
CN101199845B
(zh)
*
|
2006-12-14 |
2012-05-23 |
上海国健生物技术研究院 |
一种稳定的抗IgE人源化单抗制剂
|
CN101199483B
(zh)
*
|
2006-12-14 |
2011-01-26 |
上海中信国健药业股份有限公司 |
一种稳定的抗her2人源化抗体制剂
|
EP2114451A2
(en)
*
|
2007-01-09 |
2009-11-11 |
Wyeth a Corporation of the State of Delaware |
Anti-il-13 antibody formulations and uses thereof
|
RU2475265C2
(ru)
|
2007-01-16 |
2013-02-20 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
MX2009008692A
(es)
*
|
2007-02-16 |
2009-08-21 |
Wyeth Corp |
Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.
|
NZ578824A
(en)
|
2007-03-02 |
2012-03-30 |
Genentech Inc |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
WO2008121301A1
(en)
|
2007-03-29 |
2008-10-09 |
Abbott Laboratories |
Crystalline anti-human il-12 antibodies
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
EP2167032B1
(en)
|
2007-06-13 |
2019-08-07 |
Novo Nordisk A/S |
Pharmaceutical formulation comprising an insulin derivative
|
RU2010111120A
(ru)
|
2007-08-24 |
2011-09-27 |
Онкотерапи Сайенс, Инк. (Jp) |
Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого
|
JP2010536844A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
癌の治療標的及び診断マーカーとしてのdkk1癌遺伝子
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
KR20090056543A
(ko)
*
|
2007-11-30 |
2009-06-03 |
주식회사 녹십자 |
B형 간염 바이러스(hbv) 중화 인간 항체를 포함하는약학적 제제
|
US11197916B2
(en)
|
2007-12-28 |
2021-12-14 |
Takeda Pharmaceutical Company Limited |
Lyophilized recombinant VWF formulations
|
BRPI0821474B8
(pt)
|
2007-12-28 |
2021-05-25 |
Baxalta GmbH |
formulação farmacêutica líquida estável
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
KR101658247B1
(ko)
|
2008-01-03 |
2016-09-22 |
더 스크립스 리서치 인스티튜트 |
모듈 인식 도메인을 통한 항체 표적화
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
EP2085095B1
(en)
|
2008-01-17 |
2012-03-07 |
Philogen S.p.A. |
Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
NZ587632A
(en)
|
2008-03-14 |
2012-06-29 |
Biocon Ltd |
An anti-cd6 monoclonal antibody and a method thereof
|
CY1112212T1
(el)
*
|
2008-04-24 |
2015-12-09 |
Immatics Biotechnologies Gmbh |
Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
|
ES2342506T3
(es)
*
|
2008-04-30 |
2010-07-07 |
Immatics Biotechnologies Gmbh |
Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
KR101667062B1
(ko)
|
2008-07-15 |
2016-10-17 |
제넨테크, 인크. |
안트라시클린 유도체 접합체, 그의 제조 방법 및 항-종양 화합물로서의 그의 용도
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
SI2349314T1
(sl)
|
2008-10-21 |
2013-05-31 |
Baxter International Inc. |
Liofilizirane rekombinantne VWF formulacije
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
CA2739352C
(en)
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
EP2352513B1
(en)
|
2008-10-30 |
2016-09-14 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
EP2752189B1
(en)
|
2008-11-22 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
FR2940617B1
(fr)
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
PE20120359A1
(es)
|
2009-03-06 |
2012-04-13 |
Genentech Inc |
Formulacion con anticuerpo
|
BRPI1006270B1
(pt)
|
2009-03-25 |
2022-08-16 |
Genentech, Inc |
Anticorpo anti-a5ss1, imunoconjugado, composição farmacêutica, método in vitro ou ex vivo para detectar a proteína a5ss1, uso de um anticorpo e kit para detectar a proteína a5ss1
|
CN102325549A
(zh)
|
2009-03-31 |
2012-01-18 |
罗氏格黎卡特股份公司 |
用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症
|
AR075998A1
(es)
|
2009-04-01 |
2011-05-11 |
Genentech Inc |
Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
CA3120503A1
(en)
|
2009-07-28 |
2011-02-10 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for treating gaucher disease
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
MX336476B
(es)
|
2009-08-15 |
2016-01-20 |
Genentech Inc |
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
|
IN2012DN03025A
(pt)
|
2009-09-09 |
2015-07-31 |
Ct Se Llc |
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
SI2483305T1
(sl)
|
2009-10-01 |
2017-01-31 |
F.Hoffmann-La Roche Ag |
Večstopenjska končna filtracija imunoglobulina
|
ES2897500T3
(es)
*
|
2009-11-20 |
2022-03-01 |
Biocon Ltd |
Formulaciones de anticuerpos T1h
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
SI2512450T1
(en)
|
2009-12-15 |
2018-05-31 |
Ascendis Pharma Endocrinology Division A/S |
A dry growth hormone composition transiently bound to a polymeric carrier
|
JP2013515754A
(ja)
*
|
2009-12-29 |
2013-05-09 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規な抗体製剤
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
WO2011101796A1
(en)
|
2010-02-19 |
2011-08-25 |
Cadila Pharmaceuticals Limited |
A pharmaceutical composition of killed cells with substantially retained immunogenicity
|
CA2787952C
(en)
|
2010-02-23 |
2016-07-26 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
CN105521491B
(zh)
*
|
2010-03-01 |
2020-03-24 |
西托戴恩有限公司 |
浓缩蛋白制剂及其用途
|
EA032189B9
(ru)
|
2010-03-01 |
2019-09-30 |
БАЙЕР ХЕЛЬСКЕР ЛЛСи |
Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
|
BR112012025047A2
(pt)
|
2010-03-31 |
2016-06-21 |
Stabilitech Ltd |
formulações líquidas estabilizadas
|
DK2552410T3
(en)
|
2010-03-31 |
2019-02-18 |
Stabilitech Biopharma Ltd |
PROCEDURE FOR THE CONSERVATION OF ALUNADUVANCES AND VACCINES WITH ALUNADUVANCES
|
ES2543795T3
(es)
|
2010-03-31 |
2015-08-21 |
Stabilitech Ltd. |
Estabilización de partículas virales
|
SG10201908916UA
(en)
*
|
2010-04-27 |
2019-11-28 |
Scil Tech Gmbh |
Stable MIA/CD-RAP formulations
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
EP2585045B1
(en)
*
|
2010-06-24 |
2019-08-21 |
F.Hoffmann-La Roche Ag |
Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations
|
CN103108658B
(zh)
*
|
2010-07-02 |
2015-08-19 |
米迪缪尼有限公司 |
抗体制剂
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
WO2012012739A2
(en)
|
2010-07-22 |
2012-01-26 |
President And Fellows Of Harvard College |
Multiple input biologic classifier circuits for cells
|
WO2012012750A1
(en)
|
2010-07-23 |
2012-01-26 |
Trustees Of Boston University |
ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY
|
CA2813587C
(en)
*
|
2010-10-06 |
2019-01-15 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
JP6049625B2
(ja)
|
2010-10-27 |
2016-12-21 |
ノヴォ ノルディスク アー/エス |
様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
MX349294B
(es)
|
2010-12-02 |
2017-07-21 |
Oncolytics Biotech Inc |
Formulaciones virales liofilizadas.
|
AU2011336413B2
(en)
|
2010-12-02 |
2015-01-22 |
Oncolytics Biotech Inc. |
Liquid viral formulations
|
BR112013012422A2
(pt)
|
2010-12-21 |
2016-08-30 |
Hoffmann La Roche |
"método para produzir uma preparação de anticorpo e anticorpo anti-her2"
|
CN102028661B
(zh)
*
|
2010-12-31 |
2012-05-23 |
山东新时代药业有限公司 |
聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
|
MX349901B
(es)
|
2011-01-13 |
2017-08-18 |
Regeneron Pharma |
Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos.
|
CN107854439A
(zh)
|
2011-03-31 |
2018-03-30 |
默沙东公司 |
针对人程序性死亡受体pd‑1的抗体的稳定制剂和有关的治疗
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
TWI527590B
(zh)
*
|
2011-06-17 |
2016-04-01 |
艾瑞斯貿易公司 |
Fgf-18之凍乾調配物
|
EP2735315B1
(en)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Stable protein-containing preparation containing argininamide or valinamide
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
GB201117233D0
(en)
|
2011-10-05 |
2011-11-16 |
Stabilitech Ltd |
Stabilisation of polypeptides
|
PE20142363A1
(es)
|
2011-10-14 |
2015-01-30 |
Genentech Inc |
Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
|
CA2853112C
(en)
|
2011-10-25 |
2018-08-21 |
Onclave Therapeutics Limited |
Antibody formulations and methods
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
CN102512384B
(zh)
*
|
2011-12-29 |
2014-11-26 |
嘉和生物药业有限公司 |
一种冻干剂型蛋白组合物及其制备方法
|
DK2825558T3
(da)
|
2012-03-13 |
2019-07-22 |
Hoffmann La Roche |
Kombinationsterapi til behandling af ovariecancer
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
SG11201407512VA
(en)
*
|
2012-05-18 |
2014-12-30 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
US20140017318A1
(en)
*
|
2012-07-10 |
2014-01-16 |
Kevin O'Connell |
Method to produce a medicinal product comprising a biologically active protein and the resulting product
|
RU2015104001A
(ru)
|
2012-08-07 |
2016-09-27 |
Дженентек, Инк. |
Комбинированная терапия для лечения глиобластомы
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
SG11201504249XA
(en)
|
2012-09-02 |
2015-07-30 |
Abbvie Inc |
Methods to control protein heterogeneity
|
US20150216977A1
(en)
|
2012-09-18 |
2015-08-06 |
Adocia |
Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
|
WO2014045081A1
(en)
|
2012-09-18 |
2014-03-27 |
Adocia |
Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
|
US10253107B2
(en)
|
2012-10-26 |
2019-04-09 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
US9833410B2
(en)
|
2012-10-31 |
2017-12-05 |
Takeda Gmbh |
Lyophilized formulation comprising GM-CSF neutralizing compound
|
PL2934582T3
(pl)
*
|
2012-12-21 |
2020-08-10 |
Ichnos Sciences SA |
Formulacja przeciwciała anty-her2
|
WO2014143205A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US11433029B2
(en)
|
2013-03-15 |
2022-09-06 |
Takeda Pharmaceutical Company Limited |
Formulation of an antibody and use thereof
|
EP2968541A4
(en)
|
2013-03-15 |
2017-02-08 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
ES2843683T3
(es)
|
2013-07-23 |
2021-07-20 |
Biocon Ltd |
Uso de un ligando de CD6 y método basado en el mismo
|
EP3039039B1
(en)
|
2013-08-30 |
2021-03-10 |
Takeda GmbH |
Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
|
AR097762A1
(es)
|
2013-09-27 |
2016-04-13 |
Intervet Int Bv |
Formulaciones secas de vacunas que son estables a temperatura ambiente
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
EP3071237A1
(en)
|
2013-11-21 |
2016-09-28 |
Genmab A/S |
Antibody-drug conjugate lyophilised formulation
|
CN104707146B
(zh)
*
|
2013-12-16 |
2019-04-16 |
浙江海正药业股份有限公司 |
一种含有阿达木单抗的药物组合物
|
JP2017506640A
(ja)
|
2014-02-14 |
2017-03-09 |
セントローズ, エルエルシー |
細胞外標的化薬物共役体
|
CN103893135B
(zh)
*
|
2014-03-28 |
2017-01-11 |
中国医学科学院输血研究所 |
一种人血浆蛋白c的冻干稳定剂组合物及其用途
|
GB201406569D0
(en)
|
2014-04-11 |
2014-05-28 |
Stabilitech Ltd |
Vaccine compositions
|
RU2689145C2
(ru)
*
|
2014-04-16 |
2019-05-24 |
Биокон Лтд. |
Стабильные белковые препараты, содержащие молярный избыток сорбитола
|
EA201691883A1
(ru)
*
|
2014-05-07 |
2017-05-31 |
Такеда Гмбх |
Жидкая композиция, содержащая соединение, нейтрализующее gm-csf
|
SG11201609911YA
(en)
*
|
2014-05-28 |
2016-12-29 |
Nono Inc |
Chloride salt of tat-nr2b9c
|
ES2905777T3
(es)
|
2014-05-30 |
2022-04-12 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
|
US10562946B2
(en)
|
2014-06-20 |
2020-02-18 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
CA2952609A1
(en)
*
|
2014-06-26 |
2015-12-30 |
Amgen Inc. |
Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
WO2016037947A1
(en)
|
2014-09-10 |
2016-03-17 |
F. Hoffmann-La Roche Ag |
Galactoengineered immunoglobulin 1 antibodies
|
BR112017010498A2
(pt)
|
2014-11-19 |
2017-12-26 |
Axon Neuroscience Se |
anticorpos tau humanizados em doença de alzheimer
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
RU2021124437A
(ru)
|
2015-04-03 |
2021-09-29 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
|
ES2893239T3
(es)
|
2015-04-21 |
2022-02-08 |
Staidson Beijing Biopharmaceuticals Co Ltd |
Composición de factor de crecimiento nervioso y polvo de inyección
|
CN107660149B
(zh)
|
2015-04-21 |
2021-04-27 |
舒泰神(北京)生物制药股份有限公司 |
一种神经生长因子组合物及注射粉剂
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
ES2908009T3
(es)
|
2015-06-24 |
2022-04-27 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad adaptada
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗pcsk9阻害抗体
|
MA43023A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
UA126022C2
(uk)
|
2016-01-12 |
2022-08-03 |
Інтрон Байотекнолоджі, Інк. |
Антибактеріальна композиція й спосіб лікування стафілококових інфекцій антибактеріальною композицією
|
JP7085482B2
(ja)
*
|
2016-01-12 |
2022-06-16 |
イントロン バイオテクノロジー,インコーポレイテッド |
スタフィロコッカス感染症のための凍結乾燥製剤を製造する方法
|
BR112018014277A2
(pt)
|
2016-01-13 |
2018-12-18 |
Genmab As |
formulação, e, método de preparação de uma solução injetável de um axl-adc
|
JP2019515874A
(ja)
|
2016-03-01 |
2019-06-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
改変された細胞死誘導を有するオビヌツズマブ変異体
|
US11297828B2
(en)
|
2016-03-14 |
2022-04-12 |
The Regents Of The University Of Michigan |
Surface tension mediated lyo-processing technique for preservation of biologics
|
SG11201809959PA
(en)
|
2016-05-10 |
2018-12-28 |
Genentech Inc |
Methods of decreasing trisulfide bonds during recombinant production of polypeptides
|
KR20230162139A
(ko)
*
|
2016-06-01 |
2023-11-28 |
세르비에 아이피 유케이 리미티드 |
폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
CN110198729A
(zh)
|
2016-09-09 |
2019-09-03 |
豪夫迈·罗氏有限公司 |
卷曲蛋白的选择性肽抑制剂
|
AU2017327828B2
(en)
|
2016-09-16 |
2023-11-16 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-1 antibodies
|
KR20230164205A
(ko)
*
|
2016-10-07 |
2023-12-01 |
리제너론 파아마슈티컬스, 인크. |
실온 안정성 동결건조된 단백질
|
CA3039855A1
(en)
|
2016-10-21 |
2018-04-26 |
Biocon Limited |
A monoclonal antibody and a method of use for the treatment of lupus
|
TWI822055B
(zh)
|
2016-11-21 |
2023-11-11 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|
CA3046666A1
(en)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Method for preventing and treating tissue and organ fibrosis
|
TWI677348B
(zh)
|
2016-12-15 |
2019-11-21 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種改善心臟病變的方法
|
TW201822809A
(zh)
|
2016-12-15 |
2018-07-01 |
深圳瑞健生命科學硏究院有限公司 |
一種預防和治療高脂血症的方法
|
CN110402150A
(zh)
|
2016-12-15 |
2019-11-01 |
泰伦基国际有限公司 |
一种预防和治疗骨质疏松的药物及其用途
|
WO2018107701A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种新的降血糖和提高糖耐量的药物
|
US20190328848A1
(en)
|
2016-12-15 |
2019-10-31 |
Talengen International Limited |
Method for preventing and treating drug-induced renal injury
|
WO2018108161A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种预防和治疗肥胖症的方法和药物
|
CA3046092A1
(en)
|
2016-12-28 |
2018-07-05 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
DK3570884T3
(da)
|
2017-01-17 |
2020-11-30 |
Genentech Inc |
Subkutane HER2-antistofformuleringer
|
WO2018158716A1
(en)
|
2017-03-02 |
2018-09-07 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
CN116850283A
(zh)
|
2017-03-02 |
2023-10-10 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
CA3059820A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
US11845798B2
(en)
|
2017-05-02 |
2023-12-19 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
GB2562241B
(en)
|
2017-05-08 |
2022-04-06 |
Stabilitech Biopharma Ltd |
Vaccine compositions
|
EP3626266A4
(en)
|
2017-05-16 |
2021-04-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
CN111465408B
(zh)
|
2017-12-15 |
2023-07-04 |
泰伦基国际有限公司 |
一种预防或治疗骨关节炎的方法和药物
|
AU2019244481A1
(en)
|
2018-03-28 |
2020-10-01 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating Alzheimer's disease
|
BR112020020802A2
(pt)
*
|
2018-04-13 |
2021-01-12 |
Genentech, Inc. |
Composições farmacêuticas, composições farmacêuticas produzidas por liofilização, composições líquidas, composição farmacêutica compreendendo um imunoconjugado anti-cd79b, frasco de vidro, composição líquida compreendendo um imunoconjugado anti-cd79b, composições farmacêuticas liofilizadas, composição liofilizada, composições farmacêuticas líquidas, método para tratar um distúrbio proliferativo
|
BR112020022610A2
(pt)
|
2018-05-10 |
2021-02-09 |
Regeneron Pharmaceuticals, Inc. |
proteína de fusão de receptor de vegf de alta concentração que contém formulações
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
KR20210056288A
(ko)
|
2018-06-01 |
2021-05-18 |
타유 후아시아 바이오테크 메디컬 그룹 컴퍼니 리미티드 |
질환 또는 병태를 치료하기 위한 조성물 및 그의 용도
|
JP2021526844A
(ja)
|
2018-06-18 |
2021-10-11 |
ユーリカ セラピューティックス, インコーポレイテッド |
前立腺特異的膜抗原(psma)を標的とする構築物及びその使用
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
EP3852784A1
(en)
|
2018-09-20 |
2021-07-28 |
Mandalmed, Inc. |
Methods and compositions for preventing, treating, and reversing liver fibrosis
|
WO2020089743A1
(en)
*
|
2018-11-02 |
2020-05-07 |
Cadila Healthcare Limited |
Pharmaceutical composition of pegylated l-asparaginase
|
CN113366022A
(zh)
|
2018-11-16 |
2021-09-07 |
纪念斯隆凯特琳癌症中心 |
针对粘蛋白-16的抗体及其使用方法
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
CN111375057A
(zh)
*
|
2018-12-28 |
2020-07-07 |
上海复宏汉霖生物技术股份有限公司 |
一种包含抗Her2单克隆抗体的药物配制剂
|
CN112121150A
(zh)
*
|
2019-06-24 |
2020-12-25 |
杭州生物医药创新研究中心 |
一种成纤维细胞生长因子10冻干粉
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
EP3808777A1
(en)
|
2019-10-16 |
2021-04-21 |
Glenmark Specialty S.A. |
Stable liquid antibody formulations
|
US20230066726A1
(en)
|
2020-01-17 |
2023-03-02 |
Talengen International Limited |
Method for treatment of nerve injury and related disease
|
JP7487970B2
(ja)
|
2020-02-06 |
2024-05-21 |
タレンゲン インターナショナル リミテッド |
多発性硬化症を予防及び治療する方法並びに薬剤
|
KR20220145859A
(ko)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물, 다중 특이적 항체 및 그 용도
|
JP2023516945A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト及びその使用
|
CA3176934A1
(en)
|
2020-03-24 |
2021-09-30 |
Talengen International Limited |
Method and drug for treating parkinson's disease
|
JP2023518504A
(ja)
|
2020-03-24 |
2023-05-01 |
タレンゲン インターナショナル リミテッド |
アルツハイマー病を治療する方法及び薬剤
|
CN115666625A
(zh)
|
2020-03-24 |
2023-01-31 |
泰伦基国际有限公司 |
一种促进错误折叠蛋白及其聚集物降解的方法和药物
|
KR20220156935A
(ko)
|
2020-03-24 |
2022-11-28 |
탈렌젠 인터내셔널 리미티드 |
헌팅톤병의 치료 방법 및 약물
|
CN113993900B
(zh)
|
2020-05-27 |
2023-08-04 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别神经生长因子的抗体及其用途
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
WO2021247769A1
(en)
|
2020-06-02 |
2021-12-09 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
EP4164594A1
(en)
*
|
2020-06-12 |
2023-04-19 |
Ichnos Sciences S.A. |
Antibody formulation diluent
|
CN113827717A
(zh)
*
|
2020-06-23 |
2021-12-24 |
三生国健药业(上海)股份有限公司 |
抗her2单克隆抗体冻干制剂及制备方法
|
JP2023541217A
(ja)
|
2020-07-10 |
2023-09-29 |
シャンハイ ジェミンケア ファーマシューティカル カンパニー,リミティド |
抗IgE改変抗体及びその適用
|
MX2023001083A
(es)
|
2020-07-29 |
2023-04-10 |
Dynamicure Biotechnology Llc |
Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
|
EP4196223A1
(en)
|
2020-08-14 |
2023-06-21 |
F. Hoffmann-La Roche AG |
Methods for treating multiple sclerosis with ocrelizumab
|
CN114246944A
(zh)
*
|
2020-09-24 |
2022-03-29 |
盛禾(中国)生物制药有限公司 |
一种双特异性抗体的药物组合物及其用途
|
CN112684177B
(zh)
*
|
2020-12-17 |
2024-05-28 |
北京维德维康生物技术有限公司 |
一种乳品多因子快速检测试剂盒及其检测方法
|
JP2024509191A
(ja)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗vista構築物およびその使用
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
CN118103397A
(zh)
|
2021-07-08 |
2024-05-28 |
舒泰神(加州)生物科技有限公司 |
特异性识别tnfr2的抗体及其用途
|
EP4371572A1
(en)
|
2021-07-14 |
2024-05-22 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibody that specifically recognizes cd40 and application thereof
|
WO2023019556A1
(zh)
*
|
2021-08-20 |
2023-02-23 |
齐鲁制药有限公司 |
一种高浓度抗her2的抗体制剂及其用途
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
CN115746082A
(zh)
*
|
2022-12-02 |
2023-03-07 |
大连工业大学 |
一种调控糖基化鳕鱼蛋白结构的方法及其在制备高内相乳液中的应用
|